Today, we have recent publications in endocrinology from leading medical journals focusing on topics related to diabetes, hypothyroidism, and Cushing’s syndrome. Regular engagement with current research is essential for clinicians dedicated to delivering evidence-based care. As diagnostic, therapeutic, and management strategies continue to evolve, staying informed of the latest findings supports optimal patient outcomes.

The integration of evidence-based approaches enhances patient confidence and trust in their care providers. The following curated selection of recent journal articles provides key updates on diabetes, hypothyroidism, and Cushing’s syndrome.

Diabetes

Small Things Matter: Lack of Extraislet β Cells in Type 1 Diabetes

  • Science Advances, November 2025
  • Description: Recent three-dimensional (3D) analyses reported an abundance of small β cell-rich endocrine objects (EOs) in the human pancreas. [The researchers] used archival, immunolabeled 2D pancreas sections to assess morphological EO parameters in donors with or without type 1 diabetes (T1D), varying in age and disease duration. We confirm that abundant small, insulin-positive EOs are present in donors without diabetes and comprise most of the pancreatic endocrine area in early life. Small EOs are virtually absent in individuals with T1D, and this effect is most pronounced in children diagnosed with T1D in their earliest years.
  • Summary
  • Full Text

Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes: Design and Rationale of the REC1TE Trial

  • Diabetes, Obesity & Metabolism, October 2025
  • Description: Several clinical trials in individuals without type 1 diabetes have demonstrated improved CV outcomes when targeting residual inflammatory risk with anti-inflammatory therapies, of which especially low-dose colchicine has shown promise and has been approved by the FDA for atherosclerotic CV disease (CVD) prevention.
  • Summary
  • Full Text

Acute Brain Responses to Hypoglycaemia and Hyperglycaemia in Adolescents with Type 1 Diabetes

  • Diabetologia, October 2025
  • Description: The physiological basis of the well-described neurocognitive decrements and structural brain changes in type 1 diabetes is unclear. [The researchers] aimed to assess differences in cerebral blood flow and neural activity before, during and after induced hypoglycaemia and hyperglycaemia in adolescents with type 1 diabetes.
  • Summary
  • Full Text
Hypothyroidism

Exploratory Study of the Oral Microbiota in Pregnant Women with Hypothyroidism and Their Infants

  • BMC Pregnancy and Childbirth, November 2025
  • Description: Hypothyroidism is a metabolic disorder associated with potentially adverse maternal and neonatal outcomes. Emerging evidence suggests a link between thyroid function and the microbiota; however, little is known about the oral microbiota of pregnant women with hypothyroidism and its potential impact on that of their offspring.
  • Summary
  • Full Text

From Resistance to Relief: IV Levothyroxine in Refractory Hypothyroidism Management

  • Clinical Case Report, November 2025
  • Description: This case report details the clinical scenario of a 27-year-old female patient diagnosed with idiopathic refractory hypothyroidism. Despite adherence to prescribed oral levothyroxine therapy, she continued to experience persistent symptoms such as fatigue and cold intolerance. The exploration of her condition delved into the complexities of refractory hypothyroidism, encompassing both its diagnostic challenges and therapeutic management.
  • Summary 
  • Full Text
Cushing’s Syndrome

Clinical Efficacy and Safety of Fluconazole Treatment in Patients with Cushing’s Syndrome

  • Therapeutic Advances in Endocrinology and Metabolism
  • Description: Ketoconazole is effective for treating Cushing's syndrome (CS) but its use is limited by the risk of hepatotoxicity. Fluconazole, with similar antifungal properties, is being investigated as a potentially safer alternative for managing CS. This study aims to evaluate the efficacy and safety of fluconazole in patients with CS.
  • Summary
  • Full Text

Cyclic Cushing’s Syndrome in ACTH-Dependent Hypercortisolism Induced by the Immune Checkpoint Inhibitor Pembrolizumab

  • Archives of Endocrinology and Metabolism, September 2025
  • Description: Cushing's syndrome, characterized by exposure to elevated levels of circulating cortisol, presents a wide range of clinical features and is closely associated with increased morbidity and mortality. This article reports on a case of a patient under checkpoint inhibitor therapy, who developed cyclic adrenocorticotropic hormone-dependent hypercortisolism.
  • Summary
  • Full Text

Look forward to more journal-focused topics in the coming weeks. 

Sign up for alerts and stay informed on the latest published articles and guidelines.

Copyright © 2025 Guideline Central, all rights reserved.